Fair Value Measurements - Additional Information (Detail)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2017 USD ($) shares	Jun. 30, 2016 USD ($)	Jun. 30, 2017 USD ($) shares	Jun. 30, 2016 USD ($)	Sep. 30, 2011 shares	Mar. 31, 2017 shares	Jan. 31, 2013 shares	Dec. 31, 2012 shares
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants outstanding						432,284
Fair Value | $	$ 36,451,134		$ 36,451,134
Level 1 | Corporate Bonds
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value | $	$ 36,451,134		$ 36,451,134
Ablaris Therapeutics
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants outstanding	500,000		500,000
Duration of exchange rights			7 years
Exchange right convertible conversion ratio			0.01
Number of exchange right sold					675,000
Exchange rights
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Non-cash gain (loss) from change in fair value of the derivative liability | $			$ 28,650
Exchange rights | Ablaris Therapeutics
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Non-cash gain (loss) from change in fair value of the derivative liability | $	$ 1,150	$ (2,500)	$ 28,650	$ 2,200
2012 Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants issued to acquire Common Stock								912,543
Warrants outstanding	265,161		265,161
2013 Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants issued to acquire Common Stock							833,530
Warrants outstanding	12,123		12,123
Warrant
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Non-cash gain (loss) from change in fair value of the derivative liability | $	$ 61,915	$ (110,859)	$ 1,490,863	$ 230,082